New approaches to reduce the burden of RSV infection

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 2, 2006, Pages 173-181

  Mejías, Asunción ^a   Ramilo, Octavio ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DEXAMETHASONE; HELIOX; IMMUNOGLOBULIN; LIVE VACCINE; MEDI 524; MONOCLONAL ANTIBODY; MONTELUKAST; NITRIC OXIDE; NUMAX; PALIVIZUMAB; PLACEBO; PURIFIED F PROTEIN 1 VACCINE; PURIFIED F PROTEIN 2 VACCINE; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; SALBUTAMOL; SMALL INTERFERING RNA; SUBUNIT VACCINE; SURFACTANT; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; HEALTH EDUCATION; HUMAN; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; PATHOGENESIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRAL RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS REPLICATION;

EID: 33746825458     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.06.012     Document Type: Review

References (59)

1. Shay D.K., et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. 183 (2001) 16-22
2. Falsey A.R., et al. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352 (2005) 1749-1759
3. Thompson W.W., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
4. Stein R.T., et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354 (1999) 541-545
5. Sigurs N., et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 171 (2005) 137-141
6. Mejias A., et al. Respiratory syncytial virus pneumonia: mechanisms of inflammation and prolonged airway hyperresponsiveness. Curr. Opin. Infect. Dis. 18 (2005) 199-204
7. Buckingham S.C., et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J. Infect. Dis. 185 (2002) 1222-1228
8. Malley R., et al. Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. Pediatr. Infect. Dis. J. 19 (2000) 1-7
9. Jafri H.S., et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J. Infect. Dis. 189 (2004) 1856-1865
10. Abul-Ainine A., and Luyt D. Short term effects of adrenaline in bronchiolitis: a randomised controlled trial. Arch. Dis. Child 86 (2002) 276-279
11. Menon K., et al. A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis. J. Pediatr. 126 (1995) 1004-1007
12. Hartling L., et al. Epinephrine for bronchiolitis. Cochrane Database Syst. Rev. (2004) CD003123
13. Kellner J.D., et al. Bronchodilators for bronchiolitis. Cochrane Database Syst. Rev. (2000) CD001266
14. Dobson J.V., et al. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics 101 3 Pt 1 (1998) 361-368
15. Wainwright C., et al. A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N. Engl. J. Med. 349 (2003) 27-35
16. Richter H., and Seddon P. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. J. Pediatr. 132 (1998) 849-853
17. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering L.E. (Ed). American Academy of Pediatrics. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th edn (2003), American Academy of Pediatrics 524
18. Patel H., et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst. Rev. (2004) CD004878
19. Edell D., et al. Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity. Chest 122 (2002) 935-939
20. Ventre K., et al. Ribavirin for respiratory syncytial virus infection in the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. 4 (2004) CD000181.pub2
21. Groothuis J.R., et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J. Pediatr. 117 (1990) 792-798
22. Whimbey E., et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 16 (1995) 393-399
23. Ghosh S., et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 25 (2000) 751-755
24. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med. 167 (2003) 379-383
25. Bitko V., et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11 (2005) 50-55
26. Tibby S.M., et al. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 162 4 Pt 1 (2000) 1251-1256
27. Hoehn T., et al. Treatment of respiratory failure with inhaled nitric oxide and high- frequency ventilation in an infant with respiratory syncytial virus pneumonia and bronchopulmonary dysplasia. Respiration 65 (1998) 477-480
28. Hollman G., et al. Helium-oxygen improves clinical asthma scores in children with acute bronchiolitis. Crit. Care Med. 26 (1998) 1731-1736
29. Mejias A., et al. Respiratory syncytial virus prophylaxis. Neoreviews 6 (2005) e26-e31
30. Hall C.B., et al. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J. Pediatr. 89 (1976) 11-15
31. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
32. Feltes T.F., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143 (2003) 532-540
33. Parnes C., et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr. Pulmonol. 35 (2003) 484-489
34. DeVincenzo J.P., et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (synagis)-resistant mutants. J. Infect. Dis. 190 (2004) 975-978
35. Mejias A., et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob. Agents Chemother. 49 (2005) 4700-4707
36. Wu H., et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350 1 (2005) 126-144
37. Lagos R., et al. Administration of the Anti-RSV monoclonal antibody (MAb), Numax™, is associated with a reduction in upper airway (UA) RSV load. 4th Congress of the World Society for Pediatric Infectious Diseases. Warsaw, Poland (2005)
38. Simoes E.A., et al. Palivizumab use decrease risk of recurrent wheezing in preterm children. 4th European Respiratory Society Annual Congress. Glasgow, Scotland (2004) (Abstract No 1349)
39. Kim H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969) 422-434
40. Polack F.P., and Karron R.A. The future of respiratory syncytial virus vaccine development. Pediatr. Infect. Dis. J. 23 1 Suppl. (2004) S65-S73
41. Piedra P.A. Clinical experience with respiratory syncytial virus vaccines. Pediatr. Infect. Dis. J. 22 2 Suppl. (2003) S94-S99
42. Cannon M.J., et al. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168 (1988) 1163-1168
43. Power U.F., et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184 (2001) 1456-1460
44. Tristram D.A., et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167 (1993) 191-195
45. Paradiso P.R., et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24-48 months old. Pediatr. Infect. Dis. J. 13 (1994) 792-798
46. Munoz F.M., et al. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 (2003) 3465-3467
47. Groothuis J.R., et al. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177 (1998) 467-469
48. Piedra P.A., et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15 (1996) 23-31
49. Girard M.P., et al. A review of vaccine research and development: human acute respiratory infections. Vaccine 23 (2005) 5708-5724
50. Kim H.W., et al. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 48 (1971) 745-755
51. Wright P.F., et al. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J. Pediatr. 88 (1976) 931-936
52. Karron R.A., et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176 (1997) 1428-1436
53. Wright P.F., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182 (2000) 1331-1342
54. Karron R.A., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191 (2005) 1093-1104
55. Wright P.F., et al. The Interferon Antagonist NS2 Protein of Respiratory Syncytial Virus Is an Important Virulence Determinant for Humans. J. Infect. Dis. 193 (2006) 573-581
56. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics (1998) 102, 1211-1216
57. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics (2003) 112(6 Pt 1), 1442-1446.
58. Mejias A., et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob. Agents Chemother. 48 (2004) 1811-1822
59. Wu H., et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350 (2005) 126-144